Nvidia’s results, Indian tariffs, French markets - what’s moving markets
In a recent transaction, Mottiwala Aziz, the Chief Commercial Officer of Tarsus Pharmaceuticals, Inc. (NASDAQ:TARS), a $1.72 billion market cap company with a GOOD InvestingPro Financial Health score, sold 17,500 shares of common stock. The sale, executed on June 9, 2025, was carried out under an automatic trading plan established earlier this year. The shares were sold at a weighted average price of $43.76, with individual transactions occurring within the price range of $43.42 to $44.55. Following this transaction, Aziz retains ownership of 47,557 shares in the company. This move was facilitated by a Rule 10b5-1 trading plan, allowing for pre-determined stock sales to avoid potential conflicts of interest. Notably, analysts maintain a Strong Buy consensus on TARS, with revenue projected to grow 117% this fiscal year. For comprehensive insider trading analysis and additional insights, access the full TARS Pro Research Report on InvestingPro.
In other recent news, Tarsus Pharmaceuticals reported robust financial results for the first quarter of 2025, with net product sales reaching $78.3 million, marking a 217% year-over-year increase. This strong performance was primarily driven by the sales of their flagship product, Xtendi, with approximately 72,000 bottles dispensed. The company ended the quarter with a solid cash position of $407.9 million, bolstered by a $134.8 million equity financing. Analysts from Oppenheimer have assumed coverage of Tarsus Pharmaceuticals with an Outperform rating, citing strong sales and strategic growth initiatives, while H.C. Wainwright initiated coverage with a Buy rating, highlighting the company’s progress with XDEMVY, the first FDA-approved therapy for Demodex blepharitis.
The management of Tarsus Pharmaceuticals has noted a shift in prescribing patterns from monthly to weekly, supported by broad commercial, Medicare, and Medicaid coverage. The company’s direct-to-consumer advertising and expanded sales force have significantly contributed to its sales growth. Tarsus is also exploring global expansion opportunities for Xtendi and has plans to invest $70-$80 million in direct-to-consumer advertising for the year. Furthermore, Tarsus Pharmaceuticals is advancing its clinical pipeline, with promising developments in treatments for ocular rosacea and Lyme disease, as noted by H.C. Wainwright. These recent developments indicate a strong trajectory for Tarsus Pharmaceuticals, supported by strategic initiatives and financial stability.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.